AngioDynamics, Inc.
HealthcareNASDAQ:ANGO · NASDAQ Global Select
+$0.02 today
Vol 0.22M · Avg 0.39M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-18.6%
avg -15.4%
ROIC
-19.6%
avg -14.1%
ROA
-12.1%
avg -10.6%
Analysis
ROA is currently the strongest return metric at -12.1% versus its period average of -10.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James C. Clemmer | Chief Executive Officer, President & Director | $2.06M | — | 62 | $882,529.00 | 2.14% |
Stephen A. Trowbridge | Executive Vice President & Chief Financial Officer | $940,215.00 | — | 52 | $256,629.00 | 0.62% |
Laura Piccinini | Senior Vice President and GM of Cardiovascular & International | $842,301.00 | — | 57 | $66,756.00 | 0.16% |
Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | $739,569.00 | — | 57 | $69,903.00 | 0.17% |
Lawrence T. Weiss | Senior Vice President, Chief Legal Officer & Corporate Secretary | $696,577.00 | — | 56 | $93,597.00 | 0.23% |
Chad T. Campbell | Senior Vice President and GM of Oncology & Interventional Devices | $592,757.00 | — | 55 | $92,297.00 | 0.22% |
Saleem Cheeks | Vice President of Communications | — | — | — | — | — |
Marna I. Bronfen-Moore | Senior Vice President of Human Resources | — | — | 59 | — | — |
Kim L. Seabury | Senior Vice President of Information Technology | — | — | 59 | — | — |
Benjamin H. Davis | Senior Vice President of Business Development & Strategy | — | — | 62 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$239,532.40
Sells
0
$0.00
Net Sentiment
+$239,532.40
Net buying
Most Active
Weiss Lawrence T
1 transactions
Analysis
Insiders reported 3 buys worth $239,532.40 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $239,532.40. Weiss Lawrence T was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +17.2% | +0.6% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +17.2% over three years. Forward estimates point to Revenue at +0.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$841.97M
Sonida Senior Living, Inc.
NYSE:SNDA
$700.96M
Omeros Corporation
NASDAQ:OMER
$632.20M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
Ocugen, Inc.
NASDAQ:OCGN
$409.61M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
So-Young International Inc.
NASDAQ:SY
$244.05M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
Who manages ANGO?
AngioDynamics, Inc. (ANGO) lists 10 active executives. The top listed executive is Laura Piccinini, Senior Vice President and GM of Cardiovascular & International.
Are ANGO insiders buying or selling?
Recent insider activity shows net buying of $5.96M.
Explore More
Continue the stock analysis
Jump to another research area for this company.